Upcoming Alzheimer's Treatments: 5 Key Data Results in 2024

Recent advancements in Alzheimer's treatment are promising, with Biogen and Eisai's Leqembi receiving full approval in July, and EliLilly's donanemab potentially following suit soon. Despite initial setbacks with Aduhelm's contentious approval, the field is progressing, with Biogen discontinuing its sales and ceasing the post-approval study. Analyst Graig Suvannavejh at Mizuho Americas anticipates a combination therapy approach, similar to cancer treatments, to be the future direction.
Here are five Alzheimer's therapeutic assets with significant potential in 2024:

AL002 by Alector/AbbVie: This monoclonal antibody targets TREM2, a receptor whose impairment is linked to dementia. AL002 is in Phase II trials, with results expected in Q4 of 2024.
Fosgonimeton by Athira Pharma: This novel therapy modulates the HGF system to activate neuroprotective pathways. Despite a setback in a Parkinson's dementia trial, a Phase II/III trial for Alzheimer's is underway with results due in H2 of this year.
ALZ-801 by Alzheon: This oral treatment aims to prevent amyloid oligomers formation. It is currently in Phase III trials, with results expected mid-year.
PRX012 by Prothena: This next-gen anti-amyloid antibody has the potential to be best-in-class and is administered subcutaneously. It is in Phase I trials, with an update expected this year.
AXS-05 by Axsome Therapeutics: A repurposed antidepressant, AXS-05 targets Alzheimer's-related agitation. A pivotal Phase III study's results are anticipated in Q2 of 2024. As of January 2023, 141 drugs across 187 trials are being evaluated for Alzheimer's, signaling an innovative and dynamic landscape for treatment options. Suvannavejh expresses enthusiasm for the future of Alzheimer's disease treatment innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!